Inclusion of Subjects who are Obese in Drug Development: Current Status and Opportunities.

Vaidyanathan, Jayabharathi; Fletcher, Elimika Pfuma; Ramamoorthy, Anuradha; Madabushi, Rajanikanth; Burckart, Gilbert J

Vaidyanathan, Jayabharathi; Fletcher, Elimika Pfuma; Ramamoorthy, Anuradha; Madabushi, Rajanikanth; Burckart, Gilbert J.

Afiliación

Vaidyanathan J; Office of Clinical Pharmacology, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Fletcher EP; Office of Clinical Pharmacology, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Ramamoorthy A; Office of Clinical Pharmacology, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Madabushi R; Office of Clinical Pharmacology, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Burckart GJ; Office of Clinical Pharmacology, Office of Translational Sciences, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

J Clin Pharmacol ; 63 Suppl 2: S10-S17, 2023 11.

Article en En | MEDLINE | ID: mdl-37942907

Asunto(s)

Desarrollo de Medicamentos; Obesidad; Adulto; Humanos; Niño; Obesidad/complicaciones; Obesidad/tratamiento farmacológico; Obesidad/epidemiología

Palabras clave

FDA guidance; clinical pharmacology; clinical trial diversity; dosing; obesity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desarrollo de Medicamentos / Obesidad Límite: Adult / Child / Humans Idioma: En Revista: J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google